Straits Times Index
3,090.31 +17.32 (+0.56%) Nikkei
33,431.51 -55.38 (-0.17%) Hang Seng
16,830.30 -212.58 (-1.25%) FTSE 100
7,529.35 +75.60 (+1.01%) Bitcoin USD
38,732.01 +1,020.77 (+2.71%) CMC Crypto 200
802.76 +11.20 (+1.41%)
Johnson & Johnson (JNJ)
After hours:
- Reuters
UPDATE 2-Pfizer is sued by Texas over COVID vaccine claims
Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine. In a complaint filed in a Lubbock County state court, Paxton said it was misleading for Pfizer to claim its vaccine was 95% effective because it offered a "relative risk reduction" for people to who took it. Paxton said the claim was based on only two months of clinical trial data, and vaccine recipients' "absolute risk reduction" showed that the vaccine was just 0.85% effective.
- Business Wire
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
NEW BRUNSWICK, N.J., November 30, 2023--Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors.
- Business Wire
Johnson & Johnson MedTech Acquires Laminar, Inc.
NEW BRUNSWICK, N.J., November 30, 2023--Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Lamin
